- Fast Delivery
- 3rd Party Tested
- USA Manufactured
EU and UK, Allow 3-5 Working Days For Delivery
Supports intestinal barrier function: Larazotide has been studied for its ability to help regulate tight-junction activity and limit excessive paracellular passage across the intestinal epithelium.
May reduce gluten-related GI symptoms: Clinical trials in people with celiac disease found that certain doses, including 1 mg, reduced gastrointestinal symptoms during controlled gluten exposure.
May reduce gluten-associated immune activation: In one randomized trial, the 1 mg group had a lower increase in anti-tissue-transglutaminase IgA compared with placebo during gluten challenge.
Locally acting: Larazotide is designed to act within the intestinal tract rather than producing substantial systemic exposure.
€295.00
79 in stock
79 in stock
Store at 2–8°C to maintain quality and effectiveness.
Pens are shipped with ice packs to ensure proper temperature control.
Do not freeze, as this may compromise stability and effectiveness.
Tested by independent laboratories for heavy metals, residual solvents, and endotoxins, in line with established limits.
Batch-level traceability from production to delivery.
Certificate of analysis (CoA) available for each batch upon request.
Larazotide acetate is an investigational oral peptide designed to regulate intestinal epithelial tight junctions. Research has primarily focused on its potential to reduce gluten-related intestinal and gastrointestinal effects in people with celiac disease.
Join us for a 30-minute coaching call, led by our experienced peptide specialist. This call offers you the chance to delve into questions about peptide protocols, research, and where to begin.
